CN106138900A - 辅助治疗高血糖和糖尿病并发症的组合物及其应用 - Google Patents
辅助治疗高血糖和糖尿病并发症的组合物及其应用 Download PDFInfo
- Publication number
- CN106138900A CN106138900A CN201610818233.1A CN201610818233A CN106138900A CN 106138900 A CN106138900 A CN 106138900A CN 201610818233 A CN201610818233 A CN 201610818233A CN 106138900 A CN106138900 A CN 106138900A
- Authority
- CN
- China
- Prior art keywords
- parts
- compositions
- diabetic complication
- hyperglycemia
- probiotic bacteria
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 201000001421 hyperglycemia Diseases 0.000 title claims abstract description 52
- 239000000203 mixture Substances 0.000 title claims abstract description 42
- 208000002249 Diabetes Complications Diseases 0.000 title claims abstract description 36
- 206010012655 Diabetic complications Diseases 0.000 title claims abstract description 36
- 241000894006 Bacteria Species 0.000 claims abstract description 31
- 239000006041 probiotic Substances 0.000 claims abstract description 31
- 235000018291 probiotics Nutrition 0.000 claims abstract description 31
- 230000000529 probiotic effect Effects 0.000 claims abstract description 30
- 238000011282 treatment Methods 0.000 claims abstract description 29
- VYZAMTAEIAYCRO-UHFFFAOYSA-N Chromium Chemical compound [Cr] VYZAMTAEIAYCRO-UHFFFAOYSA-N 0.000 claims abstract description 28
- 239000011651 chromium Substances 0.000 claims abstract description 26
- 229910052804 chromium Inorganic materials 0.000 claims abstract description 26
- 241000241413 Propolis Species 0.000 claims abstract description 25
- 229940069949 propolis Drugs 0.000 claims abstract description 25
- 239000002994 raw material Substances 0.000 claims abstract description 23
- 239000003814 drug Substances 0.000 claims abstract description 20
- 240000004507 Abelmoschus esculentus Species 0.000 claims abstract description 17
- 235000003934 Abelmoschus esculentus Nutrition 0.000 claims abstract description 17
- 210000000582 semen Anatomy 0.000 claims abstract description 16
- 241000628997 Flos Species 0.000 claims abstract description 15
- 241001619461 Poria <basidiomycete fungus> Species 0.000 claims abstract description 15
- 235000013305 food Nutrition 0.000 claims abstract description 11
- 206010012601 diabetes mellitus Diseases 0.000 claims description 16
- 235000005035 Panax pseudoginseng ssp. pseudoginseng Nutrition 0.000 claims description 13
- 235000003140 Panax quinquefolius Nutrition 0.000 claims description 13
- 235000008434 ginseng Nutrition 0.000 claims description 13
- 239000009636 Huang Qi Substances 0.000 claims description 9
- 201000010099 disease Diseases 0.000 claims description 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 6
- 239000000843 powder Substances 0.000 claims description 6
- 238000002360 preparation method Methods 0.000 claims description 6
- 150000004676 glycans Chemical class 0.000 claims description 5
- 229920001282 polysaccharide Polymers 0.000 claims description 5
- 239000005017 polysaccharide Substances 0.000 claims description 5
- 235000013339 cereals Nutrition 0.000 claims description 4
- 229940046374 chromium picolinate Drugs 0.000 claims description 4
- GJYSUGXFENSLOO-UHFFFAOYSA-N chromium;pyridine-2-carboxylic acid Chemical group [Cr].OC(=O)C1=CC=CC=N1.OC(=O)C1=CC=CC=N1.OC(=O)C1=CC=CC=N1 GJYSUGXFENSLOO-UHFFFAOYSA-N 0.000 claims description 4
- 238000013329 compounding Methods 0.000 claims description 4
- 239000001963 growth medium Substances 0.000 claims description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 4
- 241000196324 Embryophyta Species 0.000 claims description 3
- 239000001387 apium graveolens Substances 0.000 claims description 3
- 238000000855 fermentation Methods 0.000 claims description 3
- 230000004151 fermentation Effects 0.000 claims description 3
- 235000001674 Agaricus brunnescens Nutrition 0.000 claims description 2
- 241000186018 Bifidobacterium adolescentis Species 0.000 claims description 2
- 241000186016 Bifidobacterium bifidum Species 0.000 claims description 2
- 240000001046 Lactobacillus acidophilus Species 0.000 claims description 2
- 235000013956 Lactobacillus acidophilus Nutrition 0.000 claims description 2
- 240000006024 Lactobacillus plantarum Species 0.000 claims description 2
- 235000013965 Lactobacillus plantarum Nutrition 0.000 claims description 2
- 241000186866 Lactobacillus thermophilus Species 0.000 claims description 2
- 240000007594 Oryza sativa Species 0.000 claims description 2
- 235000007164 Oryza sativa Nutrition 0.000 claims description 2
- 235000012055 fruits and vegetables Nutrition 0.000 claims description 2
- 229940072205 lactobacillus plantarum Drugs 0.000 claims description 2
- -1 pollen Substances 0.000 claims description 2
- 235000009566 rice Nutrition 0.000 claims description 2
- 241000193830 Bacillus <bacterium> Species 0.000 claims 1
- 244000131316 Panax pseudoginseng Species 0.000 claims 1
- 210000004369 blood Anatomy 0.000 abstract description 48
- 239000008280 blood Substances 0.000 abstract description 48
- 235000013376 functional food Nutrition 0.000 abstract description 10
- 239000000126 substance Substances 0.000 abstract description 8
- 235000015097 nutrients Nutrition 0.000 abstract description 5
- 239000013589 supplement Substances 0.000 abstract description 3
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 32
- 239000008103 glucose Substances 0.000 description 32
- 230000000694 effects Effects 0.000 description 27
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 14
- 241000208340 Araliaceae Species 0.000 description 12
- 239000007788 liquid Substances 0.000 description 10
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 9
- 230000036039 immunity Effects 0.000 description 9
- 238000000034 method Methods 0.000 description 9
- 208000024891 symptom Diseases 0.000 description 9
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 9
- 102000004877 Insulin Human genes 0.000 description 8
- 108090001061 Insulin Proteins 0.000 description 8
- 230000036772 blood pressure Effects 0.000 description 7
- 230000003203 everyday effect Effects 0.000 description 7
- 230000003345 hyperglycaemic effect Effects 0.000 description 7
- 229940125396 insulin Drugs 0.000 description 7
- 206010020772 Hypertension Diseases 0.000 description 6
- 230000033228 biological regulation Effects 0.000 description 6
- 239000008187 granular material Substances 0.000 description 6
- 230000001225 therapeutic effect Effects 0.000 description 6
- 210000002700 urine Anatomy 0.000 description 6
- 208000004880 Polyuria Diseases 0.000 description 5
- 230000037396 body weight Effects 0.000 description 5
- 230000008859 change Effects 0.000 description 5
- 230000006870 function Effects 0.000 description 5
- 230000002265 prevention Effects 0.000 description 5
- 108090000790 Enzymes Proteins 0.000 description 4
- 102000004190 Enzymes Human genes 0.000 description 4
- 241001465754 Metazoa Species 0.000 description 4
- 241000699670 Mus sp. Species 0.000 description 4
- 235000012000 cholesterol Nutrition 0.000 description 4
- 230000006378 damage Effects 0.000 description 4
- 235000005911 diet Nutrition 0.000 description 4
- 229940079593 drug Drugs 0.000 description 4
- 230000002708 enhancing effect Effects 0.000 description 4
- 230000002218 hypoglycaemic effect Effects 0.000 description 4
- 230000036737 immune function Effects 0.000 description 4
- 238000004519 manufacturing process Methods 0.000 description 4
- JEJGUIDNYBAPGN-UHFFFAOYSA-N methylenedioxydimethylamphetamine Chemical compound CN(C)C(C)CC1=CC=C2OCOC2=C1 JEJGUIDNYBAPGN-UHFFFAOYSA-N 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 230000000844 anti-bacterial effect Effects 0.000 description 3
- 210000004204 blood vessel Anatomy 0.000 description 3
- 210000004027 cell Anatomy 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- 235000009508 confectionery Nutrition 0.000 description 3
- 230000037213 diet Effects 0.000 description 3
- 230000035619 diuresis Effects 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 229930003935 flavonoid Natural products 0.000 description 3
- 150000002215 flavonoids Chemical class 0.000 description 3
- 235000017173 flavonoids Nutrition 0.000 description 3
- 230000002496 gastric effect Effects 0.000 description 3
- 210000004185 liver Anatomy 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 235000018102 proteins Nutrition 0.000 description 3
- 102000004169 proteins and genes Human genes 0.000 description 3
- 108090000623 proteins and genes Proteins 0.000 description 3
- 239000003826 tablet Substances 0.000 description 3
- SRBFZHDQGSBBOR-IOVATXLUSA-N D-xylopyranose Chemical compound O[C@@H]1COC(O)[C@H](O)[C@H]1O SRBFZHDQGSBBOR-IOVATXLUSA-N 0.000 description 2
- 229920002527 Glycogen Polymers 0.000 description 2
- 206010020710 Hyperphagia Diseases 0.000 description 2
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 2
- KAESVJOAVNADME-UHFFFAOYSA-N Pyrrole Chemical compound C=1C=CNC=1 KAESVJOAVNADME-UHFFFAOYSA-N 0.000 description 2
- 238000010171 animal model Methods 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 235000013361 beverage Nutrition 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 230000017531 blood circulation Effects 0.000 description 2
- 238000009835 boiling Methods 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 230000023852 carbohydrate metabolic process Effects 0.000 description 2
- 235000021256 carbohydrate metabolism Nutrition 0.000 description 2
- 150000001720 carbohydrates Chemical class 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 238000011443 conventional therapy Methods 0.000 description 2
- 208000029078 coronary artery disease Diseases 0.000 description 2
- 230000002526 effect on cardiovascular system Effects 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 229940096919 glycogen Drugs 0.000 description 2
- 230000002440 hepatic effect Effects 0.000 description 2
- 235000008216 herbs Nutrition 0.000 description 2
- 210000000987 immune system Anatomy 0.000 description 2
- 230000001976 improved effect Effects 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 230000010354 integration Effects 0.000 description 2
- 210000003734 kidney Anatomy 0.000 description 2
- 230000007774 longterm Effects 0.000 description 2
- 235000012054 meals Nutrition 0.000 description 2
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 2
- 231100000252 nontoxic Toxicity 0.000 description 2
- 230000003000 nontoxic effect Effects 0.000 description 2
- 230000003204 osmotic effect Effects 0.000 description 2
- 210000000496 pancreas Anatomy 0.000 description 2
- 239000001814 pectin Substances 0.000 description 2
- 229920001277 pectin Polymers 0.000 description 2
- 235000010987 pectin Nutrition 0.000 description 2
- 230000035790 physiological processes and functions Effects 0.000 description 2
- 239000002574 poison Substances 0.000 description 2
- 231100000614 poison Toxicity 0.000 description 2
- 206010036067 polydipsia Diseases 0.000 description 2
- 208000022530 polyphagia Diseases 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 230000001737 promoting effect Effects 0.000 description 2
- 239000001397 quillaja saponaria molina bark Substances 0.000 description 2
- 229930182490 saponin Natural products 0.000 description 2
- 150000007949 saponins Chemical class 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 230000000638 stimulation Effects 0.000 description 2
- 238000005728 strengthening Methods 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 239000011573 trace mineral Substances 0.000 description 2
- 235000013619 trace mineral Nutrition 0.000 description 2
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 1
- FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 description 1
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 1
- 206010001580 Albuminuria Diseases 0.000 description 1
- 206010003210 Arteriosclerosis Diseases 0.000 description 1
- 241000186012 Bifidobacterium breve Species 0.000 description 1
- 208000032841 Bulimia Diseases 0.000 description 1
- 206010006550 Bulimia nervosa Diseases 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- 241000050051 Chelone glabra Species 0.000 description 1
- 241000288570 Chionochloa conspicua Species 0.000 description 1
- 244000241257 Cucumis melo Species 0.000 description 1
- 235000015510 Cucumis melo subsp melo Nutrition 0.000 description 1
- 240000004244 Cucurbita moschata Species 0.000 description 1
- 235000009854 Cucurbita moschata Nutrition 0.000 description 1
- 235000009852 Cucurbita pepo Nutrition 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- 208000031226 Hyperlipidaemia Diseases 0.000 description 1
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 1
- 108010028554 LDL Cholesterol Proteins 0.000 description 1
- 240000008415 Lactuca sativa Species 0.000 description 1
- 235000003228 Lactuca sativa Nutrition 0.000 description 1
- 208000000501 Lipidoses Diseases 0.000 description 1
- 206010024585 Lipidosis Diseases 0.000 description 1
- 108090001030 Lipoproteins Proteins 0.000 description 1
- 102000004895 Lipoproteins Human genes 0.000 description 1
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 1
- 102000001621 Mucoproteins Human genes 0.000 description 1
- 108010093825 Mucoproteins Proteins 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 240000002853 Nelumbo nucifera Species 0.000 description 1
- 235000006508 Nelumbo nucifera Nutrition 0.000 description 1
- 235000006510 Nelumbo pentapetala Nutrition 0.000 description 1
- BGMYHTUCJVZIRP-UHFFFAOYSA-N Nojirimycin Natural products OCC1NC(O)C(O)C(O)C1O BGMYHTUCJVZIRP-UHFFFAOYSA-N 0.000 description 1
- 108091000080 Phosphotransferase Proteins 0.000 description 1
- 208000017442 Retinal disease Diseases 0.000 description 1
- 206010038923 Retinopathy Diseases 0.000 description 1
- BUGBHKTXTAQXES-UHFFFAOYSA-N Selenium Chemical compound [Se] BUGBHKTXTAQXES-UHFFFAOYSA-N 0.000 description 1
- 108010073771 Soybean Proteins Proteins 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- PJANXHGTPQOBST-VAWYXSNFSA-N Stilbene Natural products C=1C=CC=CC=1/C=C/C1=CC=CC=C1 PJANXHGTPQOBST-VAWYXSNFSA-N 0.000 description 1
- 208000005718 Stomach Neoplasms Diseases 0.000 description 1
- ZSJLQEPLLKMAKR-UHFFFAOYSA-N Streptozotocin Natural products O=NN(C)C(=O)NC1C(O)OC(CO)C(O)C1O ZSJLQEPLLKMAKR-UHFFFAOYSA-N 0.000 description 1
- 208000007271 Substance Withdrawal Syndrome Diseases 0.000 description 1
- 210000001744 T-lymphocyte Anatomy 0.000 description 1
- FPIPGXGPPPQFEQ-BOOMUCAASA-N Vitamin A Natural products OC/C=C(/C)\C=C\C=C(\C)/C=C/C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-BOOMUCAASA-N 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 208000005946 Xerostomia Diseases 0.000 description 1
- FJJCIZWZNKZHII-UHFFFAOYSA-N [4,6-bis(cyanoamino)-1,3,5-triazin-2-yl]cyanamide Chemical compound N#CNC1=NC(NC#N)=NC(NC#N)=N1 FJJCIZWZNKZHII-UHFFFAOYSA-N 0.000 description 1
- 210000001015 abdomen Anatomy 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 231100000215 acute (single dose) toxicity testing Toxicity 0.000 description 1
- 231100000403 acute toxicity Toxicity 0.000 description 1
- 230000007059 acute toxicity Effects 0.000 description 1
- 238000011047 acute toxicity test Methods 0.000 description 1
- FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 230000001093 anti-cancer Effects 0.000 description 1
- 230000003276 anti-hypertensive effect Effects 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 230000003064 anti-oxidating effect Effects 0.000 description 1
- 230000001139 anti-pruritic effect Effects 0.000 description 1
- 230000002180 anti-stress Effects 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 239000003908 antipruritic agent Substances 0.000 description 1
- 230000036528 appetite Effects 0.000 description 1
- 235000019789 appetite Nutrition 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- PYMYPHUHKUWMLA-UHFFFAOYSA-N arabinose Natural products OCC(O)C(O)C(O)C=O PYMYPHUHKUWMLA-UHFFFAOYSA-N 0.000 description 1
- 208000011775 arteriosclerosis disease Diseases 0.000 description 1
- 210000000227 basophil cell of anterior lobe of hypophysis Anatomy 0.000 description 1
- SRBFZHDQGSBBOR-UHFFFAOYSA-N beta-D-Pyranose-Lyxose Natural products OC1COC(O)C(O)C1O SRBFZHDQGSBBOR-UHFFFAOYSA-N 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 230000000975 bioactive effect Effects 0.000 description 1
- 230000036770 blood supply Effects 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- MWKXCSMICWVRGW-UHFFFAOYSA-N calcium;phosphane Chemical compound P.[Ca] MWKXCSMICWVRGW-UHFFFAOYSA-N 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 230000025938 carbohydrate utilization Effects 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 210000000748 cardiovascular system Anatomy 0.000 description 1
- 235000021466 carotenoid Nutrition 0.000 description 1
- 150000001747 carotenoids Chemical class 0.000 description 1
- 230000032677 cell aging Effects 0.000 description 1
- 230000003915 cell function Effects 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 230000003833 cell viability Effects 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 208000026106 cerebrovascular disease Diseases 0.000 description 1
- 230000001906 cholesterol absorption Effects 0.000 description 1
- BFGKITSFLPAWGI-UHFFFAOYSA-N chromium(3+) Chemical compound [Cr+3] BFGKITSFLPAWGI-UHFFFAOYSA-N 0.000 description 1
- QOWZHEWZFLTYQP-UHFFFAOYSA-K chromium(3+);triformate Chemical compound [Cr+3].[O-]C=O.[O-]C=O.[O-]C=O QOWZHEWZFLTYQP-UHFFFAOYSA-K 0.000 description 1
- 230000024203 complement activation Effects 0.000 description 1
- 230000008602 contraction Effects 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 210000004351 coronary vessel Anatomy 0.000 description 1
- 239000000287 crude extract Substances 0.000 description 1
- 239000007857 degradation product Substances 0.000 description 1
- 230000008021 deposition Effects 0.000 description 1
- 238000001784 detoxification Methods 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- 230000000378 dietary effect Effects 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 206010013781 dry mouth Diseases 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 235000013399 edible fruits Nutrition 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 235000019253 formic acid Nutrition 0.000 description 1
- 206010017758 gastric cancer Diseases 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 230000009229 glucose formation Effects 0.000 description 1
- 230000004153 glucose metabolism Effects 0.000 description 1
- 239000003292 glue Substances 0.000 description 1
- 229930182470 glycoside Natural products 0.000 description 1
- 150000002338 glycosides Chemical class 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 235000013402 health food Nutrition 0.000 description 1
- 230000003862 health status Effects 0.000 description 1
- 230000010224 hepatic metabolism Effects 0.000 description 1
- 241000411851 herbal medicine Species 0.000 description 1
- 235000003642 hunger Nutrition 0.000 description 1
- 230000002267 hypothalamic effect Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 230000008595 infiltration Effects 0.000 description 1
- 238000001764 infiltration Methods 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 239000004026 insulin derivative Substances 0.000 description 1
- 208000017169 kidney disease Diseases 0.000 description 1
- 230000003907 kidney function Effects 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 208000019423 liver disease Diseases 0.000 description 1
- 230000003908 liver function Effects 0.000 description 1
- 231100001252 long-term toxicity Toxicity 0.000 description 1
- 108010030696 low density lipoprotein triglyceride Proteins 0.000 description 1
- 230000008384 membrane barrier Effects 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 235000010755 mineral Nutrition 0.000 description 1
- 230000002107 myocardial effect Effects 0.000 description 1
- 210000004165 myocardium Anatomy 0.000 description 1
- 231100000957 no side effect Toxicity 0.000 description 1
- BGMYHTUCJVZIRP-GASJEMHNSA-N nojirimycin Chemical compound OC[C@H]1NC(O)[C@H](O)[C@@H](O)[C@@H]1O BGMYHTUCJVZIRP-GASJEMHNSA-N 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 102000020233 phosphotransferase Human genes 0.000 description 1
- 230000037081 physical activity Effects 0.000 description 1
- SIOXPEMLGUPBBT-UHFFFAOYSA-N picolinic acid Chemical compound OC(=O)C1=CC=CC=N1 SIOXPEMLGUPBBT-UHFFFAOYSA-N 0.000 description 1
- 230000000291 postprandial effect Effects 0.000 description 1
- 235000013406 prebiotics Nutrition 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 238000011321 prophylaxis Methods 0.000 description 1
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 1
- 230000008929 regeneration Effects 0.000 description 1
- 238000011069 regeneration method Methods 0.000 description 1
- 230000009711 regulatory function Effects 0.000 description 1
- 230000000630 rising effect Effects 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 239000011669 selenium Substances 0.000 description 1
- 229910052711 selenium Inorganic materials 0.000 description 1
- 230000035807 sensation Effects 0.000 description 1
- 239000002002 slurry Substances 0.000 description 1
- 235000019710 soybean protein Nutrition 0.000 description 1
- 235000020354 squash Nutrition 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- PJANXHGTPQOBST-UHFFFAOYSA-N stilbene Chemical compound C=1C=CC=CC=1C=CC1=CC=CC=C1 PJANXHGTPQOBST-UHFFFAOYSA-N 0.000 description 1
- 235000021286 stilbenes Nutrition 0.000 description 1
- 201000011549 stomach cancer Diseases 0.000 description 1
- ZSJLQEPLLKMAKR-GKHCUFPYSA-N streptozocin Chemical compound O=NN(C)C(=O)N[C@H]1[C@@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O ZSJLQEPLLKMAKR-GKHCUFPYSA-N 0.000 description 1
- 229960001052 streptozocin Drugs 0.000 description 1
- 230000009469 supplementation Effects 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- 150000003505 terpenes Chemical class 0.000 description 1
- 230000035922 thirst Effects 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 230000017423 tissue regeneration Effects 0.000 description 1
- 208000001072 type 2 diabetes mellitus Diseases 0.000 description 1
- 238000002562 urinalysis Methods 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 210000001835 viscera Anatomy 0.000 description 1
- 235000019155 vitamin A Nutrition 0.000 description 1
- 239000011719 vitamin A Substances 0.000 description 1
- 229940045997 vitamin a Drugs 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
- A61K35/741—Probiotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/56—Materials from animals other than mammals
- A61K35/63—Arthropods
- A61K35/64—Insects, e.g. bees, wasps or fleas
- A61K35/644—Beeswax; Propolis; Royal jelly; Honey
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/06—Fungi, e.g. yeasts
- A61K36/07—Basidiomycota, e.g. Cryptococcus
- A61K36/076—Poria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/13—Coniferophyta (gymnosperms)
- A61K36/15—Pinaceae (Pine family), e.g. pine or cedar
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/23—Apiaceae or Umbelliferae (Carrot family), e.g. dill, chervil, coriander or cumin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/25—Araliaceae (Ginseng family), e.g. ivy, aralia, schefflera or tetrapanax
- A61K36/258—Panax (ginseng)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
- A61K36/286—Carthamus (distaff thistle)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/39—Convolvulaceae (Morning-glory family), e.g. bindweed
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/42—Cucurbitaceae (Cucumber family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/481—Astragalus (milkvetch)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/53—Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
- A61K36/537—Salvia (sage)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/57—Magnoliaceae (Magnolia family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/60—Moraceae (Mulberry family), e.g. breadfruit or fig
- A61K36/605—Morus (mulberry)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/79—Schisandraceae (Schisandra family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/894—Dioscoreaceae (Yam family)
- A61K36/8945—Dioscorea, e.g. yam, Chinese yam or water yam
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/896—Liliaceae (Lily family), e.g. daylily, plantain lily, Hyacinth or narcissus
- A61K36/8964—Anemarrhena
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/896—Liliaceae (Lily family), e.g. daylily, plantain lily, Hyacinth or narcissus
- A61K36/8968—Ophiopogon (Lilyturf)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/899—Poaceae or Gramineae (Grass family), e.g. bamboo, corn or sugar cane
- A61K36/8994—Coix (Job's tears)
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Mycology (AREA)
- Pharmacology & Pharmacy (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Medical Informatics (AREA)
- Botany (AREA)
- Alternative & Traditional Medicine (AREA)
- Engineering & Computer Science (AREA)
- Insects & Arthropods (AREA)
- Molecular Biology (AREA)
- Animal Husbandry (AREA)
- Zoology (AREA)
- Inorganic Chemistry (AREA)
- Medicines Containing Plant Substances (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
本发明提供了一种辅助治疗高血糖和糖尿病并发症的组合物及其应用,属于医药及食品领域。该功能性食品的原料按重量份数计包括:益生菌酵素1800~2500份、蜂胶8~17份、有机三价铬0.5~1.5份、芹菜9~20份、紫薯3~8份、南瓜3~8份、薏苡仁3~8份、莴笋5~10份、咖啡黄葵5~10份、苦瓜8~15份、积雪草3~8份、丹参3~8份、红花3~8份、松花粉3~8份、知母3~8份、麦冬1~5份、五味子1~5份、山药3~8份和茯苓3~8份。该功能性食品富含多种营养素,既能补充人体所需的营养物质,又能降血糖、辅助治疗高血糖及其并发症。此外,本发明还涉及此组合物的应用。
Description
技术领域
本发明涉及医药或食品领域,具体而言,涉及一种辅助治疗高血糖和糖尿病并发症的组合物及其应用。
背景技术
当血糖值高过规定的水平时就会形成高血糖症。血糖升高,尿糖增多,可引发渗透性利尿,从而引起多尿的症状;血糖升高、大量水分丢失,血渗透压也会相应升高,高血渗可刺激下丘脑的口渴中枢,从而引起口渴、多饮的症状;由于胰岛素相对或绝对的缺乏,导致体内葡萄糖不能被利用,蛋白质和脂肪消耗增多,从而引起乏力、体重减轻;为了补偿损失的糖分,维持机体活动,需要多进食;这就形成了典型的“三多一少”症状。糖尿病病人的多饮、多尿症状与病情的严重程度呈正比。另外,值得注意的是,患者吃得越多,血糖就越高,尿中失糖也越多,饥饿感也就越厉害,最终导致了恶性循环。现有技术中多采用药物对高血糖及其并发症进行控制,且不能任意停药,患者服用麻烦。
发明内容
本发明的目的在于提供一种辅助治疗高血糖和糖尿病并发症的组合物,其能有效降低血糖、对糖尿病并发症具有很好的预防和辅助治疗作用。
本发明的另一目的在于提供一种辅助治疗高血糖和糖尿病并发症的组合物在制备用于辅助治疗高血糖和糖尿病并发症的药物中的应用。
本发明的另一目的在于提供一种辅助治疗高血糖和糖尿病并发症的组合物在制备用于辅助治疗高血糖和糖尿病并发症的食品中的应用。
本发明解决其技术问题是采用以下技术方案来实现的。
一种辅助治疗高血糖和糖尿病并发症的组合物,其原料按重量份数计包括:益生菌酵素1800~2500份、蜂胶8~17份、有机三价铬0.5~1.5份、芹菜9~20份、紫薯3~8份、南瓜3~8份、薏苡仁3~8份、莴笋5~10份、咖啡黄葵5~10份、苦瓜8~15份、积雪草3~8份、丹参3~8份、红花3~8份、松花粉3~8份、知母3~8份、麦冬1~5份、五味子1~5份、山药3~8份和茯苓3~8份。
一种辅助治疗高血糖和糖尿病并发症的组合物在制备用于辅助治疗高血糖和糖尿病并发症的药物中的应用。
一种辅助治疗高血糖和糖尿病并发症的组合物在制备用于辅助治疗高血糖和糖尿病并发症的食品中的应用。
本发明提供的一种辅助治疗高血糖和糖尿病并发症的组合物及其应用的有益效果是:本发明以益生菌酵素为基础成分,并添加蜂胶、有机三价铬等具有降血糖的功效成分,同时添加芹菜、紫薯、南瓜、薏苡仁、莴笋、咖啡黄葵、苦瓜等能够增强免疫力、抗疲劳、能改善高血糖的并发症的药食同源的成分,并且配以积雪草、丹参、红花、松花粉、知母、麦冬、五味子、山药和茯苓等中草药,进一步加强降低血糖、降血脂的作用,并改善高血糖及其并发症。本发明提供的功能性食品富含多种营养素,既能补充人体所需的营养物质,又能减少降血糖、改善高血糖及其并发症,同时,这些营养物质还能够增强人体免疫力,在保健的同时又具有很好的辅助治疗高血糖和糖尿病并发症的疗效。
具体实施方式
为使本发明实施例的目的、技术方案和优点更加清楚,下面将对本发明实施例中的技术方案进行清楚、完整地描述。实施例中未注明具体条件者,按照常规条件或制造商建议的条件进行。所用试剂或仪器未注明生产厂商者,均为可以通过市售购买获得的常规产品。
下面对本发明实施例的一种辅助治疗高血糖和糖尿病并发症的组合物及其应用进行具体说明。
一种辅助治疗高血糖和糖尿病并发症的组合物,其原料按重量份数计包括:
益生菌酵素1800~2500份、蜂胶8~17份、有机三价铬0.5~1.5份、芹菜9~20份、紫薯3~8份、南瓜3~8份、薏苡仁3~8份、莴笋5~10份、咖啡黄葵5~10份、苦瓜8~15份、积雪草3~8份、丹参3~8份、红花3~8份、松花粉3~8份、知母3~8份、麦冬1~5份、五味子1~5份、山药3~8份和茯苓3~8份。
在本发明的较佳实施例中,上述益生菌酵素2000份、蜂胶10~15份、有机三价铬0.5~1份、芹菜9~15份、紫薯3~5份、南瓜3~5份、薏苡仁3~5份、莴笋5~7份、咖啡黄葵5~7份、苦瓜8~10份、积雪草3~5份、丹参3~5份、红花3~5份、松花粉3~5份、知母3~5份、麦冬1~2份、五味子1~2份、山药3~5份和茯苓3~5份。
益生菌酵素是有多种益生菌发酵而成的制品。益生菌酵素可以促进人体的新陈代谢,分解血液中的胆固醇和高血脂蛋白,能有效减低血清胆固醇水平;分解血管内与血管壁内沉积的脂肪,使血液流通,血管弹性修复,减低血压和血脂水平;促进细胞再生,使机体产生更多的胰岛素,减低血糖水平。
具体地,益生菌酵素主要由复配益生菌在益生菌培养基上培养发酵制得,按重量份数计,复配益生菌包括:青春双歧杆菌20~100份、嗜酸乳杆菌20~100份、嗜热乳杆菌20~100份、短双歧杆菌20~100份、对岐双歧杆菌20~100份、植物乳杆菌20~100份。
益生菌培养基包括:菌类多糖、藻类多糖、植物粉、花粉、水果、蔬菜和五谷。
当纯净水温度达到35~37度时用益生菌接种,培养发酵时间为24~168小时,形成基础酵素液或在基础酵素液的基础上添加低聚果糖、抗性糊精、低聚麦芽糖、低聚木糖、胶原蛋白、大豆分离蛋白调配制粒,低温干燥制备成酵素颗粒,用于配制多种具有指向性功能性食品、保健食品、药品的天然活性原料。
该基础酵素液或酵素颗粒均可作为本发明实施例中的益生菌酵素,采用上述原料制得的益生菌酵素含有多种天然活性成分,其降血压、降血脂及降血糖的功效更强。本发明实施例以益生菌酵素为基础成分,并添加蜂胶、有机三价铬、芹菜、紫薯、南瓜、薏苡仁、莴笋、咖啡黄葵、苦瓜、积雪草、丹参、红花、松花粉、知母、麦冬、五味子、山药和茯苓这些药食同源的成分,能够有效降低血糖、降血脂,并改善高血糖及其并发症。
具体地,蜂胶所含有的丰富而独特的生物活性物质,使其具有抗菌、消炎、止痒、抗氧化、增强免疫、降血糖、降血脂、抗肿瘤等多种功能,同时蜂胶能够降低血糖、预防和治疗糖尿病及并发症。
蜂胶中的黄酮类和萜烯类物质具有促进外源性葡萄糖合成肝糖原和双向调节血糖的作用,能明显的降低血糖;蜂胶的广谱抗菌作用、促进组织再生作用,也是有效治疗各种感染的主要原因;蜂胶是一种很强的天然抗氧化剂,能显著提高SOD活性,服用蜂胶不仅可以减少自由基对细胞的伤害,还可防治高血糖的多种并发症;蜂胶的降血脂作用,改善了血液循环,并有抗氧化、保护血管效果,这是控制糖尿病及一切并发症的重要原因;蜂胶中的黄酮类、甙类等物质,能增强三磷酸腺苷酶的活性,它是人体能量的重要来源,有供应能量、恢复体力的作用,有效的缓解了高血糖患者乏力、虚弱的症状;蜂胶中的黄酮类物质、多糖物质具有调节肌体代谢,增强高血糖患者免疫能力的作用。因此,是提高肌体抗病力,提高整体素质,防止并发症的重要基础;蜂胶中含量丰富的微量元素,在糖尿病的防治中也具有作用。
三价铬是葡萄糖耐量因子的组成部分,对调节糖代谢、维持体内正常的耐量起重要作用。三价铬还作用于葡萄糖代谢中的磷酸变位酶。人吃进的淀粉可以分解为葡萄糖,在胰岛素和三价铬的共同作用下完成糖代谢。
三价铬元素对防治糖尿病、冠心病、抗衰老和提高人体免疫功能具有明显作用,动物实验和临床实验都证实,三价铬能够增强β细胞的数目和功能,促进胰岛素的合成与分泌,提高胰鸟素受体亲和力,改善糖耐量,增加细胞活力并促进糖利用。能通过精确的靶向作用,达到平衡血糖调节,稳定降低空腹血糖、餐后血糖和糖化血细蛋白,尤其是能够通过降低血浆低密度脂蛋白胆固醇和甘油三脂而有效地改善冠心病、高血压、动脉硬化等多种糖尿病并发症,大大降低了糖尿病心脑血管疾病的风险和危害。
人体对有机铬的吸收比无机铬要好,本实施例中以益生菌酵素为基础,配以蜂胶和有机三价铬,能有效地降低血糖,并改善高血糖及其并发症,大大降低了糖尿病心脑血管疾病的风险和危害。
有机三价铬中吡锭甲酸铬的吸收最为理想,其中的铬为三价铬。吡啶甲酸是存在于动物肝、肾脏的氨基酸降解产物,其作为三价铬离子的螯合载体与铬稳定结合,可通过血浆渗透压自由透过细胞膜屏障而发挥作用。由于吡啶甲酸铬属于脂溶性,故口服后在胃肠道不易被水解破坏,从而被最大限度吸收利用,多余的铬会随尿排出,不会在体内积蓄。美国食品协会调查,美国有1000万糖尿病人长期服用呲啶甲酸铬,至今未发现有任何毒副作用,因此,三价铬被糖尿病学术届誉为“矿物胰岛素”,长期补充微量元素三价铬,对治疗糖尿病患者的病情和预防、延缓及稳定改善并发症大有益处。
芹菜具有一定药理和治疗价值。芹菜含酸性的降压成分,对原发性、妊娠性及更年期高血压均有效,芹菜具有降血压、降血脂的作用。由于它们的根、茎、叶和籽都可以当药用,由于芹菜的钙磷含量较高,所以他有一定镇静和保护血管的作用,对预防高血压、动脉硬化等都十分有益。
其中,芹菜按重量份数计包括芹菜根3~5份、芹菜叶3~5份、芹菜籽3~5份。
高血糖状态下,葡萄糖不能很好地被机体吸收利用而是从尿中大量丢失,机体通过分解脂肪、蛋白质来提供能量,结果导致全身消瘦、乏力,机体免疫力下降。而本实施例中的紫薯、南瓜和咖啡黄葵均能增强人体免疫力,并且紫薯中的硒和铁是人体抗疲劳、补血的必要元素,紫薯能够清除体内自由基,抑制癌细胞中DNA的合成和癌细胞的分裂与生长,预防胃癌、肝癌等癌病的发生。而南瓜中的南瓜多糖是一种非特异性免疫增强剂,能提高机体免疫功能,促进细胞因子生成,通过活化补体等途径对免疫系统发挥多方面的调节功能。通过紫薯、南瓜和咖啡黄葵三者的配合,更有利于加强人体免疫力。
由于糖尿病患者最常见的眼部并发症是视网膜病变,而南瓜中丰富的类胡萝卜素在机体内可转化成具有重要生理功能的维生素A,从而对维持正常视觉具有重要生理功能。
高血糖患者常常伴随“三多一少”的症状,其中,多食即为机体处于半饥饿状态,能量缺乏需要补充引起食欲亢进,食量增加。而多食会导致血糖进一步升高,南瓜中的果胶能调节胃内食物的吸收速率,使糖类吸收减慢可溶性纤维素能推迟胃内食物的排空,控制饭后血糖上升。果胶还能和体内多余的胆固醇结合在一起使胆固醇吸收减少血胆固醇浓度下降。
此外,芹菜、紫薯、薏苡仁和莴笋均有利于促进排尿,对糖尿病、高血压都有一定治疗作用。同时苦瓜的粗提取物含类似胰岛素物质,有明显的降血糖作用。
将芹菜、紫薯、南瓜、薏苡仁、莴笋、咖啡黄葵和苦瓜作为原料,添加至益生菌酵素中,不仅仅能够增强人体的免疫力,同时能降血糖、降压,有效地改善糖尿病及其并发症,通过将这些原料制成功能性的食品,利用食疗对高血糖及其并发症进行改善、缓解和治疗,疗效好,患者服用方便。
此外,原料中的积雪草、丹参、红花、松花粉、知母、茯苓均能够清热利湿,消肿解毒,能够有效缓解高血糖引起的肾病或肝病等。
其中,麦冬、五味子和山药均能起到降血糖、降血压的作用,其中,麦冬通过促进胰岛细胞功能恢复、增加肝糖原、从而起到降低血糖的作用,并且麦冬还能有效地缓解口干口渴的症状,有效的改善高血糖患者多饮的症状。而五味子不仅仅能够降压,同时还能够能增强机体对非特异性刺激的防御能力,山药与五味子配合,可刺激和调节人类免疫系统。山药几乎不含脂肪,而且所含的黏蛋白能预防心血管系统的脂肪沉积,防止动脉过早地发生硬化。山药含有皂苷能够降低胆固醇和甘油三酯,对高血压和高血脂等病症有改善作用;山药可增加人体T淋巴细胞,增强糖尿病患者的免疫功能。
在本发明的优选实施例中,上述原料按重量份数计还包括:黄芪5~8份和人参5~8份。
黄芪有增强机体免疫功能、保肝、利尿、抗衰老、抗应激、降压和较广泛的抗菌作用。能消除实验性肾炎蛋白尿,增强心肌收缩力,调节血糖含量。黄芪不仅能扩张冠状动脉,改善心肌供血,提高免疫功能,而且能够延缓细胞衰老的进程。
人参能够生津,有利于使高血糖患者的渴感等症状消失或减轻,同时人参中的人参皂甙对健康人及高血脂病人均有降血脂作用。人参能增加肝脏代谢各物质的酶活性,使肝脏的解毒能力增强,从而增强机体对各种化学物质的耐受力。
黄芪和人参均属补气良药,人参偏重于大补元气,而黄芪则以补虚为主,通过将黄芪和人参配合使用,补气效果更好。同时人参、黄芩还可以与原料中的麦冬的配合,进一步加强了补气的效果。
此外,原料按重量份数计,还包括桑叶2~3份,桑叶中特有的1-脱氧野尻酶素成分,能抑制将多糖分解为葡萄糖的α-糖甘酶,从而抑制血糖的上升。桑叶处理能保护胰腺,促进胰岛素的正常分泌,还能改善高血压、减少胆固醇和甘油三酯,所以,桑叶能够有效地预防糖尿病,且能有效的抑制饭后血糖升高。
本发明提供的组合物能够有效降低血糖、对糖尿病并发症具有很好的预防和辅助治疗作用,可以用于在制备用于辅助治疗高血糖和糖尿病并发症的药物中的应用。制备得到的药物可以为口服液、片剂、胶囊剂、粉剂、颗粒剂或固体冲剂等。
本发明提供的组合物能够有效降低血糖、对糖尿病并发症具有很好的预防和辅助治疗作用,可以用于在制备用于辅助治疗高血糖和糖尿病并发症的食品中的应用。制备得到的食品具有很好的保健功效,可以为饮品、凝胶糖果或酒等。
本发明的功能性食品,不受生产加工剂型的限制。可以按从那些为了快速释放其有效成分,并持续较长时间的技术中的常规方法中获知的配方制造。
当该功能性食品为口服液或饮品时:每天服用1-2次,每次服用50ml~100ml。
当该功能性食品为片剂、胶囊或凝胶糖果时:每天服用2次,每次服用2片(粒/块),每片(粒/块)500mg~2000mg。
当该功能性食品为粉剂、颗粒剂或固体冲剂时:每天服用1-2次,每次10g~30g。
当该功能性食品为酒时:每天服用1次,每次服用10ml~50ml。
实施例一
本实施例提供了一种辅助治疗高血糖和糖尿病并发症的组合物,其原料按重量份数计包括:
益生菌酵素1800份、蜂胶8份、有机三价铬0.5份、芹菜9份、紫薯3份、南瓜3份、薏苡仁3份、莴笋5份、咖啡黄葵5份、苦瓜8份、积雪草3份、丹参3份、红花3份、松花粉3份、知母3份、麦冬1份、五味子1份、山药3份和茯苓3份。
将上述原料按配比混合,并按照常规制口服液的方法制成口服液。
实施例二
本实施例提供了一种辅助治疗高血糖和糖尿病并发症的组合物,其原料按重量份数计包括:
益生菌酵素2000份、蜂胶10份、有机三价铬1份、芹菜15份、紫薯5份、南瓜5份、薏苡仁5份、莴笋7份、咖啡黄葵7份、苦瓜10份、积雪5份、丹参5份、红花5份、松花粉5份、知母5份、麦冬2份、五味子2份、山药5份和茯苓5份。
将上述原料按配比混合,并按照常规制片剂的方法制成片剂。
实施例三
本实施例提供了一种辅助治疗高血糖和糖尿病并发症的组合物,其原料按重量份数计包括:
益生菌酵素2500份、蜂胶17份、有机三价铬1.5份、芹菜20份、紫薯8份、南瓜8份、薏苡仁8份、莴笋10份、咖啡黄葵10份、苦瓜15份、积雪草8份、丹参8份、红花8份、松花粉8份、知母8份、麦冬5份、五味子5份、山药8份、茯苓8份、黄芪7份、人参7份和桑叶2份。
将上述原料按配比混合,并按照常规制粉的方法制成粉末。
实施例四
本实施例提供了一种辅助治疗高血糖和糖尿病并发症的组合物,其原料按重量份数计包括:
益生菌酵素2200份、蜂胶11份、吡啶甲酸铬1份、芹菜16份、紫薯6份、南瓜6份、薏苡仁6份、莴笋8份、咖啡黄葵8份、苦瓜11份、积雪6份、丹参6份、红花6份、松花粉6份、知母6份、麦冬3份、五味子3份、山药6份、茯苓6份、黄芪5份、人参5份和桑叶3份。
实施例五
本实施例提供了一种辅助治疗高血糖和糖尿病并发症的组合物,其原料按重量份数计包括:
益生菌酵素2400份、蜂胶12份、吡啶甲酸铬0.5份、芹菜根3份、芹菜叶3份、芹菜籽3份、紫薯4份、南瓜4份、薏苡仁4份、莴笋6份、咖啡黄葵6份、苦瓜9份、积雪4份、丹参4份、红花4份、松花粉4份、知母4份、麦冬2份、五味子2份、山药4份、茯苓4份、黄芪8份和人参8份。
试验例
一、对本发明熬制的药膳进行动物急性毒性试验:
药物:由本发明的组方熬制的汤剂,在冰箱内保存备用。
试验动物:小白鼠,体重在20-25g,雌雄随机选择。
方法和结果:取小白鼠50只,分成5组,每组10只,饥饿15小时左右,按每只每次20ml灌喂药物,第1、2、3、4、5组分别在24小时内灌喂药物1、2、3、4、5次,观察5天,小白鼠活动正常,无毒性反应,无死亡。其中小白鼠用药量按公斤体重药量计算,表明口服液无急性毒性,临床用药剂量安全。
二、对本发明熬制的汤剂进行动物长期毒性试验:
试验动物:大白鼠,体重在120-130g,全部选择雄性大白鼠。
方法和结果:取大白鼠50只,分成5组,每组10只,其中第1、2、3、4组作为给药组,每组分别灌喂药物15ml、20ml、30ml、40ml,第五组正常喂食作为对照组,每日一次,连续灌喂90天,测体重,于最后一次给药后24小时断头处死,测血、尿常规、肝功能、肾功能,取心、肾等内脏,观察组织形态的变化,观察剂量的作用,观察饮食、活动的变化,实验证明给药组与对照组比较无显著变化,可见按公斤体重计算相对于临床50-200倍的剂量均无毒性反应,是一种安全的药物。
三、动物效果试验
临床患者中大部分都为MDDM高血糖,本实施例以链脲霉素的使用剂量用来诱导大鼠的MDDM高血糖,并随机将大鼠分为治疗组和对照组;当对治疗组MDDM高血糖大鼠以本发明的中药组合物治疗2~3周时,大鼠恢复至正常状态,而MDDM对照组的大鼠的高血糖症状仍继续存在,并且一段时间后死亡。
四、临床资料
资料与方法:收集近三年的门诊2型糖尿病病例共100例,其中男66例,女34例,患者年龄35~60岁,测定患者的空腹血糖(FBG)、餐后2h血糖(P2BG)、总胆固醇(TC)以及甘油三酯(TG)。将患者分为对照组和实验组,每组各为50例。
服用本发明实施例一提供的辅助治疗高血糖和糖尿病并发症的组合物两个疗程后,检测上述生化指标。
治疗方法:第一个疗程为30d,实验组和对照组均给予常规治疗,同时实验组给予本发明实施例1提供的口服液,每天1-2次,每次50~100mL;对照组每天给予等量的纯净水。第二个疗程为30d,实验组和对照组均未给予常规治疗,同时实验组继续给予本发明实施例1提供的口服液,每天1-2次,每次50~100mL。
检测指标:
治愈:FBG<6.1mmol/L,2h血糖(2hPG)<8.0mmol/L,TC<4.5mmol/L,TG<1.5mm01/L。无效:空腹血糖(FBG)、餐后2h血糖(P2BG)、总胆固醇(TC)以及甘油三酯(TG)均无明显改变。有效:腹血糖(FBG)、餐后2h血糖(P2BG)、总胆固醇(TC)以及甘油三酯(TG)有所改变,但未达到正常水平。
治疗效果:
对照组:治愈28例,有效13例,无效9例,总有效率为82%。
实验组:治愈42例,有效6例,无效2例,总有效率为96%。
综上,本发明提供的辅助治疗高血糖和糖尿病并发症的组合物对高血糖动物模型以及糖尿病人的治疗效果显著,且无毒副作用,具有明显的降血脂的功效,该功能性食品中具有多种功能成分,以益生菌酵素为基础成分,并添加蜂胶、有机三价铬、芹菜、紫薯、南瓜、薏苡仁、莴笋、咖啡黄葵、苦瓜、积雪草、丹参、红花、松花粉、知母、麦冬、五味子、山药和茯苓这些药食同源的成分,使机体处于健康状态,能够有效降低血糖、降血脂,并改善高血糖及其并发症。
以上所描述的实施例是本发明一部分实施例,而不是全部的实施例。本发明的实施例的详细描述并非旨在限制要求保护的本发明的范围,而是仅仅表示本发明的选定实施例。基于本发明中的实施例,本领域普通技术人员在没有作出创造性劳动前提下所获得的所有其他实施例,都属于本发明保护的范围。
Claims (10)
1.一种辅助治疗高血糖和糖尿病并发症的组合物,其特征在于,其原料按重量份数计包括:益生菌酵素1800~2500份、蜂胶8~17份、有机三价铬0.5~1.5份、芹菜9~20份、紫薯3~8份、南瓜3~8份、薏苡仁3~8份、莴笋5~10份、咖啡黄葵5~10份、苦瓜8~15份、积雪草3~8份、丹参3~8份、红花3~8份、松花粉3~8份、知母3~8份、麦冬1~5份、五味子1~5份、山药3~8份和茯苓3~8份。
2.根据权利要求1所述的辅助治疗高血糖和糖尿病并发症的组合物,其特征在于,按重量份数计,所述原料包括所述益生菌酵素2000份、所述蜂胶10~15份、所述有机三价铬0.5~1份、所述芹菜9~15份、所述紫薯3~5份、所述南瓜3~5份、所述薏苡仁3~5份、所述莴笋5~7份、所述咖啡黄葵5~7份、所述苦瓜8~10份、所述积雪草3~5份、所述丹参3~5份、所述红花3~5份、所述松花粉3~5份、所述知母3~5份、所述麦冬1~2份、所述五味子1~2份、所述山药3~5份和所述茯苓3~5份。
3.根据权利要求2所述的辅助治疗高血糖和糖尿病并发症的组合物,其特征在于,按重量份数计,所述芹菜包括芹菜根3~5份、芹菜叶3~5份和芹菜籽3~5份。
4.根据权利要求1所述的辅助治疗高血糖和糖尿病并发症的组合物,其特征在于,按重量份数计,所述原料还包括:黄芪5~8份和人参5~8份。
5.根据权利要求4所述的辅助治疗高血糖和糖尿病并发症的组合物,按重量份数计,所述原料还包括:桑叶2~3份。
6.根据权利要求1所述的辅助治疗高血糖和糖尿病并发症的组合物,其特征在于,所述有机三价铬为吡啶甲酸铬。
7.根据权利要求1所述的辅助治疗高血糖和糖尿病并发症的组合物,其特征在于,所述益生菌酵素主要由复配益生菌在益生菌培养基上培养发酵制得,按重量份数计,所述复配益生菌包括:青春双歧杆菌20~100份、嗜酸乳杆菌20~100份、嗜热乳杆菌20~100份、短双歧杆菌20~100份、双歧杆菌20~100份、植物乳杆菌20~100份。
8.根据权利要求7所述的辅助治疗高血糖和糖尿病并发症的组合物,其特征在于,所述益生菌培养基包括:菌类多糖、藻类多糖、植物粉、花粉、水果、蔬菜和五谷。
9.根据权利要求1~8任意一项所述的组合物在制备用于辅助治疗高血糖和糖尿病并发症的药物中的应用。
10.根据权利要求1~8任意一项所述的组合物在制备用于辅助治疗高血糖和糖尿病并发症的食品中的应用。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201610818233.1A CN106138900A (zh) | 2016-09-09 | 2016-09-09 | 辅助治疗高血糖和糖尿病并发症的组合物及其应用 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201610818233.1A CN106138900A (zh) | 2016-09-09 | 2016-09-09 | 辅助治疗高血糖和糖尿病并发症的组合物及其应用 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN106138900A true CN106138900A (zh) | 2016-11-23 |
Family
ID=57340831
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201610818233.1A Pending CN106138900A (zh) | 2016-09-09 | 2016-09-09 | 辅助治疗高血糖和糖尿病并发症的组合物及其应用 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN106138900A (zh) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN111134328A (zh) * | 2020-01-14 | 2020-05-12 | 何文法 | 用于防治糖尿病及并发症的保健食品组合物 |
JPWO2021085496A1 (zh) * | 2019-11-01 | 2021-05-06 |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101828660A (zh) * | 2010-05-13 | 2010-09-15 | 山东森健生物科技发展有限公司 | 一种用于高血糖病人的保健食品 |
CN102599511A (zh) * | 2012-03-23 | 2012-07-25 | 南宁市品迪生物工程有限公司 | 一种治疗糖尿病的食疗配方 |
CN103652703A (zh) * | 2013-12-01 | 2014-03-26 | 陈铭 | 一种糖尿病患者营养补充酵素食品及其制备方法 |
-
2016
- 2016-09-09 CN CN201610818233.1A patent/CN106138900A/zh active Pending
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101828660A (zh) * | 2010-05-13 | 2010-09-15 | 山东森健生物科技发展有限公司 | 一种用于高血糖病人的保健食品 |
CN102599511A (zh) * | 2012-03-23 | 2012-07-25 | 南宁市品迪生物工程有限公司 | 一种治疗糖尿病的食疗配方 |
CN103652703A (zh) * | 2013-12-01 | 2014-03-26 | 陈铭 | 一种糖尿病患者营养补充酵素食品及其制备方法 |
Non-Patent Citations (1)
Title |
---|
潘春梅主编: "《微生态制剂生产及应用》", 30 September 2014 * |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPWO2021085496A1 (zh) * | 2019-11-01 | 2021-05-06 | ||
JP7437055B2 (ja) | 2019-11-01 | 2024-02-22 | 株式会社山田養蜂場本社 | 組成物、抗酸化剤、抗糖化剤、神経突起伸長促進剤及び認知機能改善剤 |
CN111134328A (zh) * | 2020-01-14 | 2020-05-12 | 何文法 | 用于防治糖尿病及并发症的保健食品组合物 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN102907604B (zh) | 一种降糖、降压、减肥、通便养颜、抗疲劳保健品及其生产工艺 | |
CN102919836B (zh) | 一种降糖、降压、降脂、通便养颜、减肥、抗疲劳保健品及其生产工艺 | |
CN101708295B (zh) | 一种治疗糖尿病的中药制剂及其制备方法 | |
CN103099089B (zh) | 一种降糖、降压、通便减肥、抗疲劳、改善性功能保健品及其生产工艺 | |
CN101822749B (zh) | 治疗高血压高血脂的药物制剂及其制备方法 | |
CN101589801B (zh) | 一种红参蜜片的制作工艺 | |
CN104839680A (zh) | 心血管疾病医学配方食品 | |
CN105148252A (zh) | 一种复方降糖制剂 | |
CN103169793B (zh) | 一种治疗三高症的药物 | |
CN102113651A (zh) | 一种用于糖尿病人食用的馒头及其制备方法 | |
CN106387900A (zh) | 一种调节血脂、血压及血糖的组合物及其应用 | |
CN109395028A (zh) | 一种预防、治疗三高症的葛景甲参酒配方及制备方法 | |
CN106138900A (zh) | 辅助治疗高血糖和糖尿病并发症的组合物及其应用 | |
CN102150844B (zh) | 一种具有治疗糖尿病功能的挂面及其制备方法 | |
CN101336965B (zh) | 一种用于改善糖耐量、降低血糖的中成药及其制备方法 | |
CN103463407A (zh) | 理机降糖胶囊 | |
CN102698100A (zh) | 一种治疗糖尿病的口服液 | |
CN109527577A (zh) | 一种具有解酒护肝功能的组合物 | |
CN111150777A (zh) | 具有治疗糖尿病功能的中药组合物及其制备方法 | |
CN107616491A (zh) | 一种用于防治糖尿病的功能食品 | |
CN103340991B (zh) | 一种用于护理糖尿病患者的口服液及制备方法 | |
CN105733880A (zh) | 一种以榛子粕为原料酿制的复合榛子酒 | |
CN102113668A (zh) | 一种用于糖尿病人食用的速冻水饺及其制备方法 | |
CN102988747B (zh) | 一种三刺降三高的冲剂及其制备方法 | |
CN102114206A (zh) | 一种具有可恢复胰岛功能的粉剂及其制备方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
RJ01 | Rejection of invention patent application after publication | ||
RJ01 | Rejection of invention patent application after publication |
Application publication date: 20161123 |